共 50 条
- [1] First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin LymphomaCANCER DISCOVERY, 2024, 14 (01) : 66 - 75Woyach, Jennifer A.Stephens, Deborah M.Flinn, Ian W.Bhat, Seema A.Savage, Ronald E.Chai, FengEathiraj, SudharshanReiff, Sean D.Muhowski, Elizabeth M.Granlund, LindseySzuszkiewicz, LyndseyWang, WayneSchwartz, BrianGhori, RaziFarooqui, Mohammed Z. H.Byrd, John C.
- [2] Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaJOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (08) : 826 - 833Davids, Matthew S.Roberts, Andrew W.Seymour, John F.Pagel, John M.Kahl, Brad S.Wierda, William G.Puvvada, SohamKipps, Thomas J.Anderson, Mary AnnSalem, Ahmed HamedDunbar, MartinZhu, MingPeale, FranklinRoss, Jeremy A.Gressick, LoriDesai, MonaliKim, Su YoungVerdugo, MariaHumerickhouse, Rod A.Gordon, Gary B.Gerecitano, John F.
- [3] Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphomaBLOOD, 2014, 124 (08) : 1259 - 1265Barr, Paul M.Miller, Thomas P.Friedberg, Jonathan W.Peterson, Derick R.Baran, Andrea M.Herr, MeganSpier, Catherine M.Cui, HaiyanRoe, Denise J.Persky, Daniel O.Casulo, CarlaLittleton, JamieSchwartz, MarkPuvvada, SohamLandowski, Terry H.Rimsza, Lisa M.Dorr, Robert T.Fisher, Richard I.Bernstein, Steven H.Briehl, Margaret M.
- [4] Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 studyLANCET ONCOLOGY, 2018, 19 (05): : 649 - 659Italiano, AntoineSoria, Jean-CharlesToulmonde, MaudMichot, Jean-MarieLucchesi, CarloVarga, AndreaCoindre, Jean-MichelBlakemore, Stephen J.Clawson, AliciaSuttle, BenjaminMcDonald, Alice A.Woodruff, MarkRibich, ScottHedrick, EricKeilhack, HeikeThomson, BlytheOwa, TakashiCopeland, Robert A.Ho, Peter T. C.Ribrag, Vincent
- [5] MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphomaEXPERIMENTAL HEMATOLOGY, 2003, 31 (07) : 185 - 185Sanchez-Izquierdo, DBuchonnet, GSiebert, RGascoyne, RCliment, JMarin, MRosenwald, ABlesa, DPinkel, DGarcia-Conde, JDyer, MMartinez-Climent, JA
- [6] MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphomaBLOOD, 2003, 101 (11) : 4539 - 4546Sanchez-Izquierdo, DBuchonnet, GSiebert, RGascoyne, RDCliment, JKarran, LMarin, MBlesa, DHorsman, DRosenwald, AStaudt, LMAlbertson, DGDu, MQYe, HTMarynen, PGarcia-Conde, JPinkel, DDyer, MJSMartinez-Climent, JA
- [7] Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphomaBLOOD, 2021, 137 (19) : 2634 - 2645Hamadani, MehdiRadford, JohnCarlo-Stella, CarmeloCaimi, Paolo F.Reid, ErinO'Connor, Owen A.Feingold, Jay M.Ardeshna, Kirit M.Townsend, WilliamSolh, MelhemHeffner, Leonard T.Ungar, DavidWang, LuqiangBoni, JosephHavenith, KarinQin, YajuanKahl, Brad S.
- [8] Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphomaJOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) : 667 - 675Goy, AYounes, AMcLaughlin, PPro, BRomaguera, JEHagemeister, FFayad, LDang, NHSamaniego, FWang, MBroglio, KSamuels, BGilles, FSarris, AHHart, STrehu, ESchenkein, DCabanillas, FRodriguez, AM
- [9] A Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's LymphomaBLOOD, 2014, 124 (21)Christian, BethKuruvilla, JohnSmith, SonaliPorcu, PierluigiRuppert, Amy S.Byrd, John C.Grever, Michael R.Blum, Kristie A.
- [10] Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphomaCLINICAL CANCER RESEARCH, 2008, 14 (04) : 1105 - 1110Ansell, Stephen M.Witzig, Thomas E.Inwards, David J.Porrata, Luis F.Ythier, ArnaudFerrande, LeeNestorov, IvanDevries, ToddDillon, Stacey R.Hausman, DianaNovak, Anne J.